S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Here's something only a handful of people know (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Here's something only a handful of people know (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Here's something only a handful of people know (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Here's something only a handful of people know (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Here's something only a handful of people know (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Here's something only a handful of people know (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
15 A.I. Trading Opportunities a Day (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Here's something only a handful of people know (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Here's something only a handful of people know (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Forecast, Price & News

$4.24
-0.06 (-1.40%)
(As of 06/2/2023 ET)
Compare
Today's Range
$4.14
$4.40
50-Day Range
$2.33
$6.84
52-Week Range
$2.32
$15.86
Volume
338,864 shs
Average Volume
303,679 shs
Market Capitalization
$197.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25

Kinnate Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
306.8% Upside
$17.25 Price Target
Short Interest
Bearish
8.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$9.07 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.03) to ($2.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

75th out of 983 stocks

Pharmaceutical Preparations Industry

29th out of 486 stocks


KNTE stock logo

About Kinnate Biopharma (NASDAQ:KNTE) Stock

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

KNTE Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Expert Ratings for Kinnate Biopharma
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
8-K: Kinnate Biopharma Inc.
Wedbush Sticks to Their Buy Rating for Kinnate Biopharma (KNTE)
Goldman Sachs Keeps Their Buy Rating on Kinnate Biopharma (KNTE)
Kinnate Biopharma (NASDAQ:KNTE) Price Target Cut to $26.00
See More Headlines

KNTE Price History

KNTE Company Calendar

Last Earnings
5/11/2023
Today
6/02/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.25
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+296.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-116,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.78 per share

Miscellaneous

Free Float
28,922,000
Market Cap
$202.58 million
Optionable
Not Optionable
Beta
0.18

Key Executives

  • Mr. Nima Farzan M.B.A. (Age 47)
    Pres, CEO & Director
    Comp: $778.92k
  • Ms. Neha KrishnamohanMs. Neha Krishnamohan (Age 36)
    CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.
    Comp: $459.52k
  • Mr. Mark A. MeltzMr. Mark A. Meltz (Age 49)
    COO, Gen. Counsel, Treasurer & Sec.
    Comp: $586.49k
  • Ms. Priyanka Shah
    VP of Investor Relations & Communications
  • Ms. Barbara Warren
    VP of People & Culture
  • Dr. Richard Thomas Williams MBBS (Age 54)
    Ph.D., Chief Medical Officer
  • Dr. Robert Kania Ph.D.
    Sr. VP of Drug Discovery
  • Mr. Jason Hampson M.D.
    VP and Head of Regulatory Affairs & Quality













KNTE Stock - Frequently Asked Questions

Should I buy or sell Kinnate Biopharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KNTE shares.
View KNTE analyst ratings
or view top-rated stocks.

What is Kinnate Biopharma's stock price forecast for 2023?

4 Wall Street analysts have issued 1-year target prices for Kinnate Biopharma's shares. Their KNTE share price forecasts range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $17.25 in the next twelve months. This suggests a possible upside of 296.6% from the stock's current price.
View analysts price targets for KNTE
or view top-rated stocks among Wall Street analysts.

How have KNTE shares performed in 2023?

Kinnate Biopharma's stock was trading at $6.10 at the beginning of the year. Since then, KNTE stock has decreased by 28.7% and is now trading at $4.35.
View the best growth stocks for 2023 here
.

When is Kinnate Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our KNTE earnings forecast
.

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) posted its earnings results on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, meeting analysts' consensus estimates of ($0.73).

What ETF holds Kinnate Biopharma's stock ?

BlackRock Future Health ETF holds 553 shares of KNTE stock, representing 0.02% of its portfolio.

When did Kinnate Biopharma IPO?

(KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.

What is Kinnate Biopharma's stock symbol?

Kinnate Biopharma trades on the NASDAQ under the ticker symbol "KNTE."

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.89%), Foresite Capital Management V LLC (4.24%), FMR LLC (3.54%), State Street Corp (1.00%), Geode Capital Management LLC (0.96%) and Charles Schwab Investment Management Inc. (0.30%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams.
View institutional ownership trends
.

How do I buy shares of Kinnate Biopharma?

Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kinnate Biopharma's stock price today?

One share of KNTE stock can currently be purchased for approximately $4.35.

How much money does Kinnate Biopharma make?

Kinnate Biopharma (NASDAQ:KNTE) has a market capitalization of $202.58 million. The company earns $-116,270,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

How can I contact Kinnate Biopharma?

The official website for the company is www.kinnate.com. The company can be reached via phone at 858-299-4699 or via email at investors@kinnate.com.

This page (NASDAQ:KNTE) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -